Editor's note: Seeking Alpha is proud to welcome Matthew J Smith as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own op ...

AdaptHealth (AHCO) 2025 Conference May 21, 2025 08:00 AM ET Speaker0 Relations in the room. Thank you guys very much for joining us. Thanks for having us, Ben. Yeah. I just wanted to kinda recap some of the dynamics that are going on in the quarter. Diabetes revenue declined 8%, but it's largely as expected. We're doing a overhaul of that segment, but you noticed some better than expected sequential developments and setups. Maybe you can kinda walk us through what you're seeing and and kinda how we you're f ...

Financial Performance - Net revenue for the three months ended March 31, 2025, was $777,882, a decrease of 1% from $792,497 in the same period of 2024[20]. - Operating income decreased to $23,170 for Q1 2025, down 54% from $50,531 in Q1 2024[20]. - Net loss attributable to AdaptHealth Corp. was $7,207 for Q1 2025, compared to a net loss of $2,134 in Q1 2024, representing a significant increase in losses[20]. - The company reported a comprehensive loss of $6,754 for Q1 2025, compared to a comprehensive loss of $253 in Q1 2024[22]. - The net loss for the three months ended March 31, 2025, was $6,079,000, compared to a net loss of $1,109,000 for the same period in 2024[26]. - Adjusted EBITDA for the three months ended March 31, 2025, was $127,938,000, down from $158,485,000 in the same period of 2024, indicating a decline of about 19.3%[100]. - The diluted net loss per share for the three months ended March 31, 2025, was $(0.05), consistent with the diluted net loss per share for the same period in 2024[154]. Revenue Breakdown - For the three months ended March 31, 2025, total net revenue was $777.9 million, a decrease of 1.8% from $792.5 million in the same period of 2024[73]. - Insurance revenue for the three months ended March 31, 2025, was $454.2 million, down 6.0% from $483.4 million in 2024[73]. - Patient pay revenue increased by 14.0% to $126.2 million in Q1 2025, compared to $110.7 million in Q1 2024[73]. - Net sales revenue from Sleep Health segment was $241.2 million in Q1 2025, slightly up from $237.6 million in Q1 2024[75]. - Revenue from fixed monthly equipment reimbursements totaled $249.5 million in Q1 2025, down from $254.3 million in Q1 2024[75]. - The Sleep Health segment generated net revenue of $316,351,000 for the three months ended March 31, 2025, compared to $325,334,000 in 2024, a decrease of approximately 2.9%[95]. - The Wellness at Home segment reported net revenue of $157,206,000 for the three months ended March 31, 2025, slightly up from $156,044,000 in 2024[95]. Assets and Liabilities - Total assets as of March 31, 2025, were $4,437,350, a decrease from $4,486,947 as of December 31, 2024[18]. - Total liabilities decreased to $2,863,496 as of March 31, 2025, down from $2,908,829 at the end of 2024[18]. - The company’s accumulated deficit increased to $569,385 as of March 31, 2025, from $562,178 as of December 31, 2024[18]. - As of March 31, 2025, the assets held for sale amounted to $101,449,000, an increase from $52,748,000 as of December 31, 2024[84]. - The total liabilities held for sale increased to $17,514,000 as of March 31, 2025, from $7,043,000 as of December 31, 2024[84]. - Long-term debt as of March 31, 2025, totaled $1.941 billion, down from $1.965 billion as of December 31, 2024[124]. Cash Flow and Liquidity - Cash and cash equivalents decreased to $53,650 as of March 31, 2025, from $109,747 as of December 31, 2024, indicating a liquidity contraction[18]. - Net cash provided by operating activities increased to $95,527,000 in Q1 2025, up from $49,035,000 in Q1 2024, representing a 95% increase[26]. - Cash at the end of the period was $53,650,000, down from $79,566,000 at the end of Q1 2024, indicating a decrease of approximately 32.6%[26]. - The company’s cash paid for interest was $45,969,000 in Q1 2025, down from $50,259,000 in Q1 2024, indicating a decrease of 8.6%[26]. Expenses - General and administrative expenses were $86,854 for Q1 2025, slightly down from $89,041 in Q1 2024[20]. - The company reported depreciation and amortization expenses of $94,345,000 for Q1 2025, slightly up from $92,876,000 in Q1 2024[26]. - The company incurred equity-based compensation expenses of $5,296,000 in Q1 2025, compared to $4,533,000 in Q1 2024, reflecting a 16.9% increase[26]. - The company recognized depreciation expense of $89.2 million for the three months ended March 31, 2025, compared to $87.3 million for the same period in 2024[85]. - The company incurred finance lease costs of $3,374,000 for amortization of right-of-use (ROU) assets in Q1 2025, which is an increase of 49.8% compared to $2,255,000 in Q1 2024[164]. - The company recorded an income tax expense of $0.9 million for the three months ended March 31, 2025, a significant decrease from $6.6 million in the same period of 2024[167]. Compliance and Legal Matters - The company has no material accruals related to lawsuits, claims, or investigations at this time, indicating a stable legal standing[171]. - The company is fully cooperating with multiple investigations regarding potential violations of the False Claims Act, but the impact on financial conditions remains uncertain[172][179][181]. Debt and Financing - The Company issued $600.0 million aggregate principal amount of 5.125% senior unsecured notes in August 2021, maturing on March 1, 2030[132]. - The Company recognized a loss of $0.7 million in other comprehensive income due to cash flow hedge accounting for the three months ended March 31, 2025[121]. - The Company made a voluntary repayment of $20.9 million on the 2024 Term Loan during the three months ended March 31, 2025[130]. - As of March 31, 2025, the outstanding borrowings under the 2024 Term Loan were $525.0 million, with a quarterly principal repayment requirement of $4.1 million through September 30, 2026, increasing to $8.1 million from December 31, 2026, through June 30, 2029[130]. - The maximum amount the Company could borrow under the 2024 Revolver while remaining compliant with financial debt covenants was $277.6 million[131].

AdaptHealth (AHCO) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Company Participants Suzanne Foster - Chief Executive Officer & DirectorJason Clemens - Chief Financial OfficerMeghan Holtz - VP, Healthcare Services Equity ResearchKevin Caliendo - Managing DirectorBen Hendrix - Vice PresidentMathew Blackman - Managing DirectorWhit Mayo - Senior Managing Director Conference Call Participants Pito Chickering - AnalystEric Coldwell - Senior Research AnalystJohn Pinney - Analyst Operator Good day, everyone, and ...

Group 1: Earnings Performance - AdaptHealth Corp. reported quarterly earnings of $0.01 per share, matching the Zacks Consensus Estimate, compared to $0.02 per share a year ago [1] - The company posted revenues of $777.88 million for the quarter, exceeding the Zacks Consensus Estimate by 1.72%, but down from $792.5 million year-over-year [2] - Over the last four quarters, AdaptHealth has surpassed consensus EPS estimates three times [1][2] Group 2: Stock Performance and Outlook - AdaptHealth shares have declined approximately 8.6% since the beginning of the year, while the S&P 500 has decreased by 3.9% [3] - The company's earnings outlook will be crucial for future stock movements, with current consensus EPS estimates at $0.28 for the coming quarter and $1.12 for the current fiscal year [4][7] - The current Zacks Rank for AdaptHealth is 3 (Hold), indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical - Products industry, to which AdaptHealth belongs, is currently ranked in the bottom 26% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that investors should monitor these revisions closely [5]

Financial Supplement Q1 2025 Disclaimer This presentation contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements, which express management's current views concerning future business, events, trends, contingencies, financial performance, or financial condition, appear at various places in this communication and may use words like "aim," "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "forecast," "future," "goal, ...

AdaptHealth (AHCO) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Speaker0 Good day, everyone, and welcome to today's Adapt Health's First Quarter twenty twenty five Earnings Release. Today's speakers will be Suzanne Foster, Chief Executive Officer of Adapt Health and Jason Clements, Chief Financial Officer of Adapt Health. Before we begin, I'd like to remind everyone that statements included in this conference call and in the press release issued today may constitute forward looking statements within the m ...

Exhibit 99.1 Financial Outlook The Company is updating previous financial guidance for fiscal year 2025 to account for the disposition of certain incontinence assets, as follows: FOR IMMEDIATE RELEASE ADAPTHEALTH CORP. ANNOUNCES FIRST QUARTER 2025 RESULTS CONSHOHOCKEN, Pa. – May 6, 2025 - AdaptHealth Corp. (NASDAQ: AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, ann ...

Core Viewpoint - AdaptHealth Corp. (AHCO) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Outlook - The Zacks rating upgrade reflects optimism about AdaptHealth's earnings outlook, which is expected to lead to increased buying pressure and a rise in stock price [3][5]. - The company is projected to earn $1.12 per share for the fiscal year ending December 2025, representing a year-over-year increase of 16.7% [8]. Earnings Estimate Revisions - Over the past three months, the Zacks Consensus Estimate for AdaptHealth has increased by 6%, indicating a positive trend in earnings estimate revisions [8]. - The Zacks Rank system effectively utilizes earnings estimate revisions to classify stocks, with a strong correlation between these revisions and near-term stock movements [6][7]. Institutional Investor Influence - Changes in earnings estimates significantly impact institutional investors' valuation models, leading to buying or selling actions that affect stock prices [4]. - The Zacks rating system maintains a balanced approach, with only the top 20% of stocks receiving a 'Strong Buy' or 'Buy' rating, highlighting AdaptHealth's strong position in earnings estimate revisions [9][10].

Investors with an interest in Medical - Products stocks have likely encountered both AdaptHealth Corp. (AHCO) and Stryker (SYK) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates ...